In the Claims:

Amend the claims as follows:

1-24 (Cancelled)

25. (Currently amended) A composition of cells useful for repair of damaged heart muscle of a patient, comprising myoblasts that have been transgenically transformed to express a cellular integration factor selected from the group consisting of an angiogenesis factor, vascular endothelial growth factor, fibroblast growth factor, TGF-beta, platelet derived growth factor, angiogenin, pleiotrophin, and interlukin-8.

26. (Previously presented) A composition as described in claim 25, further comprisiong a cellular integration factor selected from the group consisting of a migration factor, a scaffolding protein, PDGF, HGF, fibronectin, MMP-1, MMP-2, laminin, laminin-1, fibronectin, type I collagen, type II collagen, type IV collagen, thrombospondin-I, lecithin-oxytetracycline-collagen matrix, a galactin, galectin-1, vitronectin, and von Willebrand protein.

27. (Currently amended) A composition of cells useful for repair of damaged heart muscle of a patient, comprising myoblasts and an effective amount of a cellular integration factor selected from the group consisting of an angiogenesis factor, vascular endothelial growth factor, fibroblast growth factor, platelet derived growth factor, angiogenin, TGF-beta, pleiotrophin, and interleukin-8a migration factor, a scaffolding protein, PDGF, HGF, fibronectin, MMP-1, MMP-2, laminin, laminin-1, fibronectin, type I collagen, type II collagen, type IV collagen,

thrombospondin-I, lecithin-oxytetracycline-collagen matrix, a galactin, galectin-1, vitronectin, and von Willebrand protein.

28. (New) A composition of cells as recited in claim 25, wherein the cells have been further treated by exposure to chondroitin sulfate.

29. (New) A composition of cells as recited in claim 28, wherein the cells have been exposed to chondroitin sulfate at a final concentration of between 5 micromolar to 5 millimolar.

30. (New) A composition of cells as recited in claim 25, wherein the cells have been obtained by a process that uses autograft transfer from the same patient.

31. (New) A composition of cells as recited in claim 25, further comprising an angiogenesis factor in a slow release form.

32. (New) A composition of cells as recited in claim 31, further comprising non-myoblast cells that produce the angiogenesis factor.

33. (New) A composition of cells as recited in claim 25, further comprising a pharmaceutical compound that alters hyperpolarization.

34. (New) A composition of cells as recited in claim 27, wherein the cells have been further treated by exposure to chondroitin sulfate.

35. (New) A composition of cells as recited in claim 34, wherein the cells have been exposed to chondroitin sulfate at a final concentration of between 5 micromolar to 5 millimolar.

36. (New) A composition of cells as recited in claim 27, wherein the cells have been obtained by a process that uses autograft transfer from the same patient.

37. (New) A composition of cells as recited in claim 27, further comprising an angiogenesis factor in a slow release form.

38. (New) A composition of cells as recited in claim 37, further comprising non-myoblast cells that produce the angiogenesis factor.

39. (New) A composition of cells as recited in claim 27, further comprising a pharmaceutical compound that alters hyperpolarization.

Summary

Entry of the response to the restriction requirement and the claim amendment cheerfully are requested. If a telephone conference can expedite any issue, the Examiner cordially is invited to contact applicant's representative at 202-204-4728.

Respectfully submitted,

Marvin A. Motsenbocker
Registration No. 36,614

Date: March 13, 2007

NDQ&M WATCHSTONE LLP
Customer No.: 58789
1300 Eye Street, N.W.
1000 West Tower
Washington, DC 20005
Telephone: (202) 659-0100
Facsimile: (202) 659-0105